Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Résumé Online Appendices All Versions of this Article: cmaj.080486v1 180/1/32    most recent Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loke, Y. K. Articles by Furberg, C. D. Search for Related Content PubMed PubMed Citation Articles by Loke, Y. K., MBBS MD Articles by Furberg, C. D., MD PhD Related Collections Diabetes Adverse drug reactions Related Articles

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

From the School of Medicine, Health Policy and Practice (Loke), University of East Anglia, Norwich, UK; and the Section on General Internal Medicine, Department of Medicine (Singh), and the Division of Public Health Sciences (Furberg), Wake Forest University School of Medicine, Winston-Salem, USA

Correspondence to: Dr. Yoon K. Loke, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK NR4 7TJ; fax 44 1603 593752 y.loke{at}uea.ac.uk

Background: Rosiglitazone and pioglitazone may increase the incidence of fractures. We aimed to determine systematically the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect of the therapy on bone density.

Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), other trial registries and product information sheets through June 2008. We selected long-term ( 1 year) randomized controlled trials involving patients with type 2 diabetes and controlled observational studies that described the risk of fractures or changes in bone density with thiazolidinediones. We calculated pooled odds ratios (ORs) for fractures and the weighted mean difference in bone density.

Results: We analyzed data from 10 randomized controlled trials involving 13 715 participants and from 2 observational studies involving 31 679 participants. Rosiglitazone and pioglitazone were associated with a significantly increased risk of fractures overall in the 10 randomized controlled trials (OR 1.45, 95% confidence interval [CI] 1.18–1.79; p < 0.001). Five randomized controlled trials showed a significantly increased risk of fractures among women (OR 2.23, 95% CI 1.65–3.01; p < 0.001) but not among men (OR 1.00, 95% CI 0.73–1.39; p = 0.98). The 2 observational studies demonstrated an increased risk of fractures associated with rosiglitazone and pioglitazone. Bone mineral density in women exposed to thiazolidinediones was significantly reduced at the lumbar spine (weighted mean difference –1.11%, 95% CI –2.08% to –0.14%; p = 0.02) and hip (weighted mean difference –1.24%, 95%CI –2.34% to –0.67%; p < 0.001) in 2 randomized controlled trials.

Interpretation: Long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes.

This article has been cited by other articles:

				A. Dixit and P. Pandey Beware fractures BMJ, September 29, 2009; 339(sep29_3): b3957 - b3957. [Full Text]

				C. R. Dormuth, G. Carney, B. Carleton, K. Bassett, and J. M. Wright Thiazolidinediones and Fractures in Men and Women Arch Intern Med, August 10, 2009; 169(15): 1395 - 1402. [Abstract] [Full Text] [PDF]

				D. H. Solomon, S. M. Cadarette, N. K. Choudhry, C. Canning, R. Levin, and T. Sturmer A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2792 - 2798. [Abstract] [Full Text] [PDF]

				T. Reblin Thiazolidinedione use and the risk of fractures Can. Med. Assoc. J., April 14, 2009; 180(8): 841 - 841. [Full Text] [PDF]

				Y. K. Loke and S. Singh Two of the authors respond: Can. Med. Assoc. J., April 14, 2009; 180(8): 842 - 843. [Full Text] [PDF]

				K. A. Toulis, D. G. Goulis, and A. D. Anastasilakis Thiazolidinedione use and the risk of fractures Can. Med. Assoc. J., April 14, 2009; 180(8): 841 - 842. [Full Text] [PDF]

				Rosiglitazone, Pioglitazone, and Fractures: A Meta-Analysis Journal Watch (General), January 27, 2009; 2009(127): 6 - 6. [Full Text]

				L. L. Lipscombe MD MSc Thiazolidinediones: Do harms outweigh benefits? Can. Med. Assoc. J., January 6, 2009; 180(1): 16 - 17. [Full Text] [PDF]

eLetters:

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2009, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.